Pegaspargase
| Systematic (IUPAC) name | |
|---|---|
|
Pegylated E. coli L-asparagine amidohydrolase | |
| Clinical data | |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a695031 |
| Pregnancy category |
|
| Legal status |
|
| Identifiers | |
| CAS Number |
130167-69-0  |
| ATC code | L01XX24 |
| DrugBank |
DB00059 |
| ChemSpider | none |
| UNII |
7D96IR0PPM |
| Chemical data | |
| Formula | C1377H2208N382O442S17 |
| Molar mass | 31731.9 g/mol |
| (verify) | |
Pegaspargase /pəˈɡæspərɡeɪz/, trade name Oncaspar, is a modified enzyme used as an antineoplastic agent. It is a form of L-asparaginase[1] which has undergone PEGylation.
It is used in the treatment of acute lymphoblastic leukemia.[2][3]
See also
References
- ↑ "UNM Cancer Center". Archived from the original on September 3, 2006. Retrieved 2007-08-28.
- ↑ Graham ML (2003). "Pegaspargase: a review of clinical studies". Adv. Drug Deliv. Rev. 55 (10): 1293–302. doi:10.1016/S0169-409X(03)00110-8. PMID 14499708.
- ↑ Patel SS, Benfield P (Jun 1996). "New drug profile: pegaspargase (Polyethylene Glycol L-Asparaginase)". Clinical Immunotherapeutics 5 (6): 492–496.
| ||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Sunday, January 17, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.